Comparative Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) and Statins on Postprandial Triglyceride-Rich Lipoprotein Metabolism

OBJECTIVE—: Inhibition of PCSK9 (proprotein convertase subtilisin/kexin type 9) and statins are known to lower plasma LDL (low-density lipoprotein)-cholesterol concentrations. However, the comparative effects of these treatments on the postprandial metabolism of TRLs (triglyceride-rich lipoproteins)...

Descripción completa

Detalles Bibliográficos
Autores principales: Chan, Dick C., Watts, Gerald F., Somaratne, Ransi, Wasserman, Scott M., Scott, Rob, Barrett, P. Hugh R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2018
Materias:
Clinical and Population Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6039422/
https://www.ncbi.nlm.nih.gov/pubmed/29880491
http://dx.doi.org/10.1161/ATVBAHA.118.310882

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6039422/
https://www.ncbi.nlm.nih.gov/pubmed/29880491
http://dx.doi.org/10.1161/ATVBAHA.118.310882

Ejemplares similares